Takeda unveils new dengue vaccine manufacturing plant in Germany

The Singen vaccine plant will be utilized for formulation, fill, finish and secondary packaging of the dengue vaccine candidate starting with the packaging line.

Topics: Takeda dengue vaccine plant Germany

Takeda invested more than 130 million Euro and will employ up to 200 employees in the vaccine plant.

According to the World Health Organization (WHO), dengue is the fastest spreading mosquito-borne viral disease, which is estimated to cause approximately 390 million infections and 20,000 deaths globally each year.

Takeda’s dengue vaccine candidate is currently being investigated in the pivotal Phase 3, multi-centered, global, double blind, randomized, placebo-controlled trial to evaluate the efficacy, safety and immunogenicity of a tetravalent dengue vaccine administered subcutaneously in healthy children. ■